Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized, Active-controlled, Phase 2a Study to Evaluate the Pharmacokinetics and Safety of Alpibectir/Ethionamide in Combination With the Standard Regimen in Patients With Tuberculosis Meningitis.

NCT07350174 is registered in ClinicalTrials.gov with BioVersys AG as lead sponsor.

NCT NCT07350174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07350174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized, Active-controlled, Phase 2a Study to Evaluate the Pharmacokinetics and Safety of Alpibectir/Ethionamide in Combination With the Standard Regimen in Patients With Tuberculosis Meningitis.
Lead sponsor
BioVersys AG
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 30, 2026
Completion date
October 30, 2028
Enrollment
64 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis meningitis